Skip to main content

New Products: Foundation Medicine's FoundationOne; Omixon's Target

Premium

Foundation Medicine has launched FoundationOne, its targeted sequencing-based cancer test, which screens for mutations in 200 cancer-related genes. The test is offered out of the company's CLIA certified laboratory on the Illumina HiSeq 2000 with a turnaround time of 21 days. The test must be ordered by a physician and is used to match genomic alterations with a targeted therapy or clinical trial.


Omixon has launched Target, software analysis for targeted sequencing data designed for diagnostic labs looking to adopt next-gen sequencing. According to the company, Target uses profiles with parameters set up for the particular gene target, to ensure precision for diverse assays, such as oncogenes or immune-system genes.

The Scan

WHO OKs Emergency Use of Sinopharm Vaccine

The World Health Organization has granted emergency approval for Sinopharm's SARS-CoV-2 vaccine, the Guardian reports.

Scientific Integrity Panel to Meet

According to the Associated Press, a new US scientific integrity panel is to meet later this week.

Trying in the Eye

NPR reports that a study of Editas Medicine's CRISPR therapy for Leber congenital amaurosis has begun.

PLOS Papers on Cerebellum Epigenetics, Copy Number Signature Tool, Acute Lung Injury Networks

In PLOS this week: epigenetics analysis of brain tissue, bioinformatics tool to find copy number signatures in cancer, and more.